The very first clinical trial to do so used the maxillary sinuses for delivery of recombinant AAV2 containing the CFTR gene (AAV2-CFTR) in ten CF patients, demonstrating a safe, successful transduction of targeted cells and a detected function restoration of the sinuses [288]. The gene discussed is CFTR; the disease is cystic fibrosis.